Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital, led by Kevin Kotler, in a filing with the Securities and Exchange Commission, reported initiating a position in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). The fund currently owns 896,100 shares, which is equivalent to 5.55% of the common stock of the company.

Kevin Kotler

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) is a Massachusetts based company, focused on discovering and developing protein therapeutics to treat ocular diseases. The stock of the company began trading on the NASDAQ Global Market a couple of weeks ago. The company raised $50.0 million in an initial public offering of 5.00 million shares of its common stock at a price of $10.00 per share.

At the end of the fourth quarter of 2013, total value of the equity portfolio of Broadfin Capital was $1.45 billion. Kevin Kotler’s Broadfin Capital had the largest investment in Aerie Pharmaceuticals Inc (NASDAQ:AERI), the position amassing 391,232 shares, worth $702.65 million. The next big holding in its equity portfolio is the specialty pharmaceutical company, Depomed Inc (NASDAQ:DEPO), in which the fund reported 4.74 million shares, with a value of $50.2 million. Another significant investment of the fund is in Lannett Company, Inc. (NASDAQ:LCI) with a reported stake of 1.34 million shares, worth $44.35 million.

Early this year, the fund revealed a new stake in Retrophin Inc (NASDAQ: RTRX). Broadfin Capital now owns 1.61 million shares in this biotechnology company, which is equivalent to 6.93% of the common stock of Retrophin Inc (NASADQ:RTRX).

Late last year, Kevin Kotler’s Broadfin Capital upped its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to 4.5 million shares from around 3.6 million shares held earlier. Around the same period, the fund also increased its position in Derma Sciences Inc (NASDAQ:DSCI) to 871,600 shares from 771, 600 shares held earlier.

Disclosure: none

Recommended Reading:

Edward Gilhuly and Sageview Capital’s New Stock Moves

Lance Helfert and Paul Orfalea’s Top Holdings and Latest Sales

New Picks of Steve Cohen’s SAC Capital Advisors

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!